Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, was submitted on September 17, 2025. The report covers the period ending June 30, 2025, and primarily serves to disseminate a press release dated September 17, 2025 (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided filing text does not contain specific financial data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not available in this document.
Material Changes
The filing text does not provide comparative financial data or details regarding material changes versus prior periods.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) but does not include the text of that release. Therefore, specific guidance, management commentary, risks, contingencies, or unusual items are not detailed in the provided content.
Investor Verification Checklist
- Review the full text of the press release dated September 17, 2025 (Exhibit 99.1) for specific operational updates or financial announcements.
- Verify the company's latest audited financial statements in the most recent Form 20-F for detailed revenue and cash flow metrics.
- Confirm the status of any clinical trials or regulatory approvals mentioned in the referenced press release.